Scaling up methadone maintenance treatment for opioid-dependent prisoners in Iran

References 

1. Bayanzadeh SA, Afshar P. A study of effectiveness of pharmacological and psychological interventions in reducing drug related harms and improving psychological status of drug dependent prisoners. Tehran: Tehran Psychiatric Institute, Iran Prison Organization, and United Nations Office on Drugs and Crime, Iran; 2004;
2. Buavirat A, Page-Shafer K, van Griensven GJ, Mandel JS, Evans J, Chuaratanaphong J, et al. Risk of prevalent HIV infection associated with incarceration among injecting drug users in Bangkok, Thailand: Case-control study. British Medical Journal. 2003;326(7384):308
3. Dolan KA, Shearer J, MacDonald M, Mattick RP, Hall W, Wodak AD. A randomised controlled trial of methadone maintenance treatment versus wait list control in an Australian prison system. Drug and Alcohol Dependence. 2003;72(1):59–65
   • Abstract
   • Full Text
   • Full-Text PDF (200 KB)
   • CrossRef
4. Dolan KA, Shearer J, White B, Zhou J, Kaldor J, Wodak AD. Four-year follow-up of imprisoned male heroin users and methadone treatment: Mortality, re-incarceration and hepatitis C infection. Addiction. 2005;100(6):820–828
   • MEDLINE
   • CrossRef
5. Dolan KA, Wodak A. HIV transmission in a prison system in an Australian State. The Medical Journal of Australia. 1999;171(1):14–17
6. Eshrati B, Asl RT, Dell CA, Afshar P, Millson PM, Kamali M, et al. Preventing HIV transmission among Iranian prisoners: Initial support for providing education on the benefits of harm reduction practices. Harm Reduction Journal. 2008;5:21
7. Gossop M, Marsden J, Stewart D, Treacy S. Outcomes after methadone maintenance and methadone reduction treatments: Two-year follow-up results from the National Treatment Outcome Research Study. Drug and Alcohol Dependence. 2001;62(3):255–264
   • Abstract
   • Full Text
   • Full-Text PDF (102 KB)
   • CrossRef
8. Health and Treatment Headquarter of Iran Prison Organization . An overview on HIV/AIDS in prisons of Islamic Republic of Iran. Tehran: Iran Prison Organization; 2006;
9. Institute of Medicine . Preventing HIV infection among injecting drug users in high risk countries: An assessment of the evidence. Washington, DC: National Academic Press; 2006;
10. Kheirandish P, Seyedalinaghi SA, Hosseini M, Jahani MR, Shirzad H, Foroughi M, et al. Prevalence and correlates of HIV infection among male injection drug users in detention, Tehran, Iran. Journal of Acquired Immune Deficiency Syndromes. 2009;
11. Larney S, Dolan K. A literature review of international implementation of opioid substitution treatment in prisons: Equivalence of care?. European Addiction Research. 2009;15(2):107–112
    • CrossRef
12. Macalino GE, Vlahov D, Sanford-Colby S, Patel S, Sabin K, Salas C, et al. Prevalence and incidence of HIV, hepatitis B virus, and hepatitis C virus infections among males in Rhode Island prisons. American Journal of Public Health. 2004;94(7):1218–1223
    • MEDLINE
    • CrossRef
13. Razzaghi E, Nassirimanesh B, Afshar P, Ohiri K, Claeson M, Power R. HIV/AIDS harm reduction in Iran. Lancet. 2006;368(9534):434–435
    • Full Text
    • Full-Text PDF (41 KB)
    • CrossRef
14. Razzaghi EM, Rahimi MA. Injection drug use in Tehran. Tehran, Iran: Tehran University of Medical Sciences; 2005;
15. Stark K, Bienzle U, Vonk R, Guggenmoos-Holzmann I. History of syringe sharing in prison and risk of hepatitis B virus, hepatitis C virus, and human immunodeficiency virus infection among injecting drug users in Berlin. International Journal of Epidemiology. 1997;26(6):1359–1366
    • MEDLINE
    • CrossRef
16. Taylor A, Goldberg D, Emslie J, Wrench J, Gruer L, Cameron S, et al. Outbreak of HIV infection in a Scottish prison. British Medical Journal. 1995;310(6975):289–292
17. Tomasino V, Swanson AJ, Nolan J, Shuman HI. The Key Extended Entry Program (KEEP): A methadone treatment program for opiate-dependent inmates. The Mount Sinai Journal of Medicine. 2001;68(1):14–20
18. UNAIDS . Islamic Republic of Iran country report on monitoring of the United Nations General Assembly special session on HIV and AIDS declaration of commitment. Office of the Under-secretary for Health, Ministry of Health and Medical Education, Centre for Diseases Management; 2006;
19. WHO . Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence. WHO; 2009;
20. WHO/UNODC/UNAIDS . Substitution maintenance treatment in the management of opioid dependence and HIV/AIDS prevention: Position paper. Geneva: World Health Organization, United Nations Office on Drugs and Crime, Joint United Nations Programme on HIV/AIDS.; 2004;
21. WHO/UNODC/UNAIDS . Interventions to address HIV in prisons: Drug dependence treatments. Geneva: World Health Organization; 2007;
22. Zamani S, Farnia M, Tavakoli S, Gholizadeh M, Nazari M, Seddighi AA, et al. A qualitative inquiry into methadone maintenance treatment for opioid-dependent prisoners in Tehran, Iran. International Journal of Drug Policy. 2009;
23. Zamani S, Kihara M, Gouya MM, Vazirian M, Nassirimanesh B, Ono-Kihara M, et al. High prevalence of HIV infection associated with incarceration among community-based injecting drug users in Tehran, Iran. Journal of Acquired Immune Deficiency Syndromes. 2006;42(3):342–346
24. Zamani S, Kihara M, Gouya MM, Vazirian M, Ono-Kihara M, Razzaghi EM, et al. Prevalence of and factors associated with HIV-1 infection among drug users visiting treatment centers in Tehran, Iran. AIDS. 2005;19(7):709–716
    • MEDLINE